Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2017 6
2018 2
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W, Chuner J, Quanquan S, Zhimin Y, Tongxin L, Jiping L, Sakamoto M, Peng W, Kaiyuan S, Weifeng Q, Zhenfu F, Yangming J. Fangzheng W, et al. Among authors: tongxin l. Oncotarget. 2017 Dec 14;8(70):115469-115479. doi: 10.18632/oncotarget.23300. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383174 Free PMC article.
Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S, Tongxin L, Zhenfu F, Yangming J. Wang F, et al. Among authors: tongxin l. Medicine (Baltimore). 2020 Sep 25;99(39):e22283. doi: 10.1097/MD.0000000000022283. Medicine (Baltimore). 2020. PMID: 32991429 Free PMC article. Clinical Trial.
Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W, Quanquan S, Chuner J, Lei W, Fengqin Y, Zhimin Y, Tongxin L, Min X, Peng W, Haitao J, Aizawa R, Sakamoto M, Yuezhen W, Zhenfu F. Fangzheng W, et al. Among authors: tongxin l. Oncotarget. 2017 May 27;8(57):96798-96808. doi: 10.18632/oncotarget.18245. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228572 Free PMC article.
Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W, Chuner J, Zhiming Y, Tongxin L, Fengqin Y, Lei W, Bin L, Fujun H, Ming C, Weifeng Q, Zhenfu F. Fangzheng W, et al. Among authors: tongxin l. Oncol Res. 2018 Mar 5;26(2):277-287. doi: 10.3727/096504017X15079846743590. Epub 2017 Oct 18. Oncol Res. 2018. PMID: 29046165 Free PMC article.
Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis.
Fangzheng W, Chuner J, Zhimin Y, Quanquan S, Tongxin L, Min X, Peng W, Bin L, Sakamoto M, Yuezhen W, Fengqin Y, Zhenfu F, Yangming J. Fangzheng W, et al. Among authors: tongxin l. Oncotarget. 2017 Oct 6;8(55):94117-94128. doi: 10.18632/oncotarget.21587. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212214 Free PMC article.
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W, Chuner J, Haiyan Q, Quanquan S, Zhimin Y, Tongxin L, Jiping L, Peng W, Kaiyuan S, Zhenfu F, Yangming J. Fangzheng W, et al. Among authors: tongxin l. Medicine (Baltimore). 2019 Dec;98(51):e18484. doi: 10.1097/MD.0000000000018484. Medicine (Baltimore). 2019. PMID: 31861031 Free PMC article.
Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S, Tongxin L, Min X, Peng W, Bin L, Aizawa R, Sakamoto M, Zhenfu F. Fangzheng W, et al. Among authors: tongxin l. Oncotarget. 2017 Aug 7;8(53):91150-91161. doi: 10.18632/oncotarget.20017. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207632 Free PMC article.
11 results